Glioblastoma (brain tumors): Targeting a rare but deadly disease

While less than 1% of people will be diagnosed with malignant brain tumors, only 1 in 3 will survive 5 years.1

Indoximod may help the immune system outsmart glioblastomas2

NewLink Genetics’ indoximod is a small-molecule indoleamine 2,3-dioxygenase (IDO) pathway inhibitor that has the potential to disrupt mechanisms by which tumors evade the immune system.3,4


Learn more about the indoximod study in glioblastoma



1. National Cancer Institute. SEER stat fact sheets: brain and other nervous system. Accessed October 4, 2015. 2. National Institutes of Health. Study of IDO inhibitor and temozolomide for adult patients with primary malignant brain tumors. Accessed October 4, 2015. 3. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34(3):137-143. 4. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like helper T cells. J Immunol. 2009;183(4):2475-2483.